A controlled trial of the effects of esmolol on cardiac function

Area of Science:

• Anesthesiology
• Cardiovascular Pharmacology

Background:

• Esmolol hydrochloride is an ultra-short-acting beta-blocker used for managing tachycardia and hypertension.
• Its hemodynamic effects require careful evaluation, especially in surgical settings.

Purpose of the Study:

• To evaluate the dose-dependent effects of esmolol hydrochloride on key hemodynamic parameters.
• To compare the impact of two different esmolol doses against a placebo in healthy surgical patients.

Main Methods:

• A placebo-controlled, double-blind, randomized trial involving 60 healthy adult patients.
• Standardized general anesthesia with a laryngeal mask airway was administered.
• Hemodynamic variables including heart rate, mean arterial pressure, stroke volume, and cardiac output were measured via Doppler ultrasonography at 1-minute intervals for 5 minutes post-injection.

Main Results:

• Both 100 mg and 200 mg doses of esmolol hydrochloride significantly decreased heart rate, mean arterial pressure, stroke volume, and cardiac output compared to placebo (P < 0.05).
• The 200 mg dose exhibited a greater reduction in heart rate, stroke volume, and cardiac output than the 100 mg dose (P < 0.05).
• Hemodynamic depression was most pronounced at 2 minutes post-injection, with incomplete recovery observed by 5 minutes.

Conclusions:

• Esmolol hydrochloride effectively reduces hemodynamic variables in a dose-dependent manner during minor orthopedic surgery under general anesthesia.
• The observed hemodynamic depression warrants consideration for perioperative management and patient monitoring.